Literature DB >> 28058187

A Simplified In Vitro Teratoma Assay for Pluripotent Stem Cells Injected Into Rodent Fetal Organs.

Shigeo Masuda1, Takashi Yokoo2, Naomi Sugimoto3, Masako Doi3, Shuh-Hei Fujishiro1, Kengo Takeuchi4, Eiji Kobayashi3, Yutaka Hanazono1.   

Abstract

Teratoma formation assays are established methods for evaluating the pluripotency of embryonic stem (ES) cells and induced pluripotent stem (iPS) cells. Teratoma formation in immunodeficient mice takes approximately 2 months. Here, we have developed a novel assay system for developing teratomas in vitro from ES cells and iPS cells in a short period. In vitro culture of ES, iPS, and mesenchymal stem cells (MSCs) in fetal rat metanephroi for 1 week resulted in distinct cell-dependent distribution patterns: Pluripotent cells (ES and iPS cells) formed aggregated masses, whereas MSCs showed disseminated distribution. The aggregated masses that had developed from ES cells and iPS cells after 2 weeks of culture comprised teratomas, though they were largely composed of immature components. Furthermore, in vitro organ culture for 1 week followed by relay transplantation into immunodeficient mice resulted in considerably rapid growing teratomas (teratomas developed in 4 weeks) having similar pathological features as of the teratomas developed using conventional 7-week in vivo teratoma formation assays. In addition, the initial cell number required in the in vitro assay was 1 × 103 cells, which was about 1% of the number of cells required in the conventional in vivo teratoma formation assays. These results suggest that the in vitro teratoma assay is a rapid and convenient screening system and might be an alternative method for developing teratomas for investigating the pluripotency of ES cells and iPS cells.

Entities:  

Keywords:  ES cells; Fetal rat metanephros; Organ culture; Teratoma formation; iPS cells

Year:  2012        PMID: 28058187      PMCID: PMC5196933          DOI: 10.3727/215517912X639351

Source DB:  PubMed          Journal:  Cell Med        ISSN: 2155-1790


  15 in total

1.  Stem cells. Setting standards for human embryonic stem cells.

Authors:  Ali H Brivanlou; Fred H Gage; Rudolf Jaenisch; Thomas Jessell; Douglas Melton; Janet Rossant
Journal:  Science       Date:  2003-05-09       Impact factor: 47.728

2.  A call to standardize teratoma assays used to define human pluripotent cell lines.

Authors:  Franz-Josef Müller; Johanna Goldmann; Peter Löser; Jeanne F Loring
Journal:  Cell Stem Cell       Date:  2010-05-07       Impact factor: 24.633

3.  Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart.

Authors:  Harald C Ott; Thomas S Matthiesen; Saik-Kia Goh; Lauren D Black; Stefan M Kren; Theoden I Netoff; Doris A Taylor
Journal:  Nat Med       Date:  2008-01-13       Impact factor: 53.440

4.  Broader implications of defining standards for the pluripotency of iPSCs.

Authors:  George Q Daley; M William Lensch; Rudolf Jaenisch; Alex Meissner; Kathrin Plath; Shinya Yamanaka
Journal:  Cell Stem Cell       Date:  2009-03-06       Impact factor: 24.633

5.  Induced pluripotent stem cells in long-QT syndrome.

Authors:  Shigeo Masuda; Yutaka Hanazono
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

6.  Human mesenchymal stem cells in rodent whole-embryo culture are reprogrammed to contribute to kidney tissues.

Authors:  Takashi Yokoo; Toya Ohashi; Jin Song Shen; Ken Sakurai; Yoichi Miyazaki; Yasunori Utsunomiya; Masanori Takahashi; Yoshio Terada; Yoshikatsu Eto; Tetsuya Kawamura; Noriko Osumi; Tatsuo Hosoya
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

7.  The growth factor environment defines distinct pluripotent ground states in novel blastocyst-derived stem cells.

Authors:  Yu-Fen Chou; Hsu-Hsin Chen; Maureen Eijpe; Akiko Yabuuchi; Joshua G Chenoweth; Paul Tesar; Jun Lu; Ronald D G McKay; Niels Geijsen
Journal:  Cell       Date:  2008-10-31       Impact factor: 41.582

8.  Role of ERas in promoting tumour-like properties in mouse embryonic stem cells.

Authors:  Kazutoshi Takahashi; Kaoru Mitsui; Shinya Yamanaka
Journal:  Nature       Date:  2003-05-29       Impact factor: 49.962

9.  Generation of germline-competent induced pluripotent stem cells.

Authors:  Keisuke Okita; Tomoko Ichisaka; Shinya Yamanaka
Journal:  Nature       Date:  2007-06-06       Impact factor: 49.962

Review 10.  Mesenchymal stromal cells: current understanding and clinical status.

Authors:  Husein K Salem; Chris Thiemermann
Journal:  Stem Cells       Date:  2010-03-31       Impact factor: 6.277

View more
  2 in total

1.  Emerging innovation towards safety in the clinical application of ESCs and iPSCs.

Authors:  Shigeo Masuda; Shigeru Miyagawa; Satsuki Fukushima; Nagako Sougawa; Emiko Ito; Maki Takeda; Atsuhiro Saito; Yoshiki Sawa
Journal:  Nat Rev Cardiol       Date:  2014-08-05       Impact factor: 32.419

2.  The Anterior Eye Chamber as a Visible Medium for In Vivo Tumorigenicity Tests.

Authors:  Emi Inagaki; Eri Arai; Shin Hatou; Tomoko Sayano; Hiroko Taniguchi; Kazuno Negishi; Yae Kanai; Yasunori Sato; Hideyuki Okano; Kazuo Tsubota; Shigeto Shimmura
Journal:  Stem Cells Transl Med       Date:  2022-08-23       Impact factor: 7.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.